Orum Therapeutics

오름테라퓨틱 · 475830

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$993M (₩1.4T)

Overview

Orum Therapeutics is a biotech company listed on KOSDAQ, Korea's tech-focused stock exchange, that develops experimental cancer medicines designed to destroy disease-causing proteins inside specific cells.

Its core platform, which it calls DAC (Degrader-Antibody Conjugate), combines two established drug-design approaches: the precise cell-targeting ability of antibody-drug conjugates and the protein-destroying mechanism of targeted protein degradation. The company's pipeline is built entirely around this proprietary dual-precision technology, which it applies across multiple disease areas.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$17.1K

▼ −99.9% YoY

Operating profit · FY2025

−US$37.5M

Loss widened

Net income · FY2025

−US$30.4M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2024	FY2025
Revenue	US$15.1M(₩20.9B)	US$17.1K(₩23.6M)
Operating profit	−US$6M(−₩8.3B)	−US$37.5M(−₩51.8B)
Net income	−US$4.2M(−₩5.7B)	−US$30.4M(−₩42B)

Revenue

FY2024US$15.1M
FY2025US$17.1K

Operating profit

FY2024−US$6M
FY2025−US$37.5M

Net income

FY2024−US$4.2M
FY2025−US$30.4M

Key ratios (FY2025)

ROE

-32.1%

Debt/Eq

29.4%

Op. margin

-219651.4%

Net margin

-178105.4%

Rev. YoY

▼ −99.9%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?